http://www.proactiveinvestors.com.au Proactiveinvestors RSS feed en Thu, 23 Nov 2017 12:56:18 +1100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[News - Novogen signs agreement to facilitate brain cancer clinical trials in China ]]> http://www.proactiveinvestors.com.au/companies/news/187174/novogen-signs-agreement-to-facilitate-brain-cancer-clinical-trials-in-china-187174.html Novogen Limited (ASX:NRT) has entered into an agreement with Cedrus Investments Ltd for advisory services to establish a corporate structure focused on the Greater China region.

Novogen is an emerging oncology-focused biotechnology company, based in Sydney.

The new corporate entity will enable Novogen to interact directly with the Chinese Food and Drug Administration (CFDA) for future clinical trials in China.

The agreement defines the key terms, with most of the work expected to be conducted in the first half of calendar 2018.

It is also expected that the Chinese entity will be a Wholly Foreign Owned Enterprise (WFOE), headquartered in Shanghai.

Novogen is developing GDC-0084, a novel targeted therapy that modulates the PI3K pathway to treat glioblastoma multiforme (GBM).

GBM is the most common and most aggressive form of brain cancer.

Licensed from Genentech in late 2016, GDC-0084 is anticipated to enter phase II clinical trials this year.

Novogen has several preclinical programs in active development, the largest of which is substantially funded by a CRC-P grant from the Australian Federal Government.

The partnership with Cedrus Investments will help Novogen to engage with researchers and investors to support the development of its current and future pipeline.

]]>
Tue, 14 Nov 2017 08:43:00 +1100 http://www.proactiveinvestors.com.au/companies/news/187174/novogen-signs-agreement-to-facilitate-brain-cancer-clinical-trials-in-china-187174.html
<![CDATA[News - Novogen: Access latest PPT from Proactive's CEO Sessions ]]> http://www.proactiveinvestors.com.au/companies/news/176394/novogen-access-latest-ppt-from-proactive-s-ceo-sessions-176394.html Novogen’s (ASX:NRT, NASDAQ:NVGN) chief executive officer, Dr James Garner, joined Proactive's CEO Sessions in Melbourne on Tuesday, 11th April.

Novogen is an emerging oncology drug developer with two clinical-stage programs.

The company's value proposition is to partner with big pharma for late-stage development to bring to market.

ACCESS THE FULL PRESENTATION HERE

]]>
Thu, 13 Apr 2017 13:00:00 +1000 http://www.proactiveinvestors.com.au/companies/news/176394/novogen-access-latest-ppt-from-proactive-s-ceo-sessions-176394.html
<![CDATA[News - Novogen on track to commence phase II trial of brain cancer therapy ]]> http://www.proactiveinvestors.com.au/companies/news/176238/novogen-on-track-to-commence-phase-ii-trial-of-brain-cancer-therapy-176238.html Novogen (ASX:NRT, NASDAQ:NVGN) is on track to commence the phase II human trial of its GDC-0084 brain cancer therapy in calendar year 2017.

GDC-0084 is an orally-administered therapy which is under development as a treatment for glioblastoma multiforme (GBM), the most common and most aggressive form of brain cancer.

GBM affects circa 130,000 patients worldwide annually, and has one of the poorest outcomes of any cancer, with only 3-5% of patients alive five years after diagnosis.

The GDC-0084 therapy is designed to inhibit tumour growth by targeting an important biochemical control mechanism that is thought to be critical to the growth of the tumour.

GDC-0084 was licensed by Novogen from Genentech, a member of the Roche Group, in October 2016.

Since the transaction, Novogen has completed the transfer of the FDA Investigational New Drug (IND) application from Genentech to Novogen.

Novogen has also taken possession of around 48.8 kilograms of premanufactured drug substance that had been prepared by Genentech in anticipation of a phase II study.

This material is now being formulated into oral capsules for use in the phase II clinical trial.

The study will be a randomized, two-arm study with 200 patients receiving either GDC-0084 or temozolomide as maintenance therapy after completion of standard radiotherapy treatment.

The primary endpoint of the study will be progression-free survival (PFS), with patients followed for overall survival.

PFS can be considered an acceptable endpoint for approval of oncology drugs by FDA.

Novogen anticipates that the phase II study will commence in the second half of calendar 2017, and will take circa 18 months to reach full recruitment, with PFS data available 12 months thereafter.

]]>
Mon, 10 Apr 2017 15:30:00 +1000 http://www.proactiveinvestors.com.au/companies/news/176238/novogen-on-track-to-commence-phase-ii-trial-of-brain-cancer-therapy-176238.html
<![CDATA[News - Novogen to strengthen patent position ]]> http://www.proactiveinvestors.com.au/companies/news/160160/novogen-to-strengthen-patent-position-63839.html Novogen (ASX:NRT; NASDAQ:NVGN) will strengthen its intellectual property position on its key anti-tropomyosin technology platform, lodging two new patents.

Novogen has two drug technology platforms, the Superbenzopyran (SBP) and anti-tropomyosin (ATM) with established patent positions.

Acting CEO Iain Ross, said the company currently had an extensive program of activities underway including the lead pre-clinical programs and discovery programs.

The medicinal chemistry programs have identified two promising drug candidates (Cantrixil and Anisina), which Novogen is progressing down the translational development path.

Novogen is searching for a world class CEO and to beef up its project and manufacturing management support ranks.

The company held $45 million in cash in June.

 


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Wed, 05 Aug 2015 12:30:00 +1000 http://www.proactiveinvestors.com.au/companies/news/160160/novogen-to-strengthen-patent-position-63839.html
<![CDATA[News - Novogen Limited drug could improve effectiveness of chemotherapy in children ]]> http://www.proactiveinvestors.com.au/companies/news/160159/novogen-limited-drug-could-improve-effectiveness-of-chemotherapy-in-children-63443.html Novogen Limited (ASX:NRT, NASDAQ:NVGN) has completed a pre-clinical in vivo proof of concept study demonstrating its Anisina drug has the potential to improve the effectiveness of chemotherapy in children and reduce life-long side-effects.

The anti-tropomyosin drug significantly improved the efficacy of standard of care microtubule targeting compound, vincristine, in an animal model of neuroblastoma.

It shows that animals can be dosed with a proprietary formulation of Anisina in combination with the standard of care and recapitulate in an animal model of neuroblastoma the same effect as observed in the test tube.

Neuroblastoma is a cancer that is most frequently observed in the young with more than 90% of diagnoses occurring in children under 5 years of age.

It is considered to be the most common solid tumour in children outside the brain.



Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Tue, 14 Jul 2015 13:00:00 +1000 http://www.proactiveinvestors.com.au/companies/news/160159/novogen-limited-drug-could-improve-effectiveness-of-chemotherapy-in-children-63443.html
<![CDATA[News - These are the biggest ASX% Gainers at mid-day ]]> http://www.proactiveinvestors.com.au/companies/news/160158/these-are-the-biggest-asx-gainers-at-mid-day-61910.html Wednesday’s ASX % Gainers at midday.

NameCodeLastChangeVolume Stone Resources ASX:SHK $0.002 100% 2,000,000 Novogen Limited ASX:NRT $0.367 26.6% 32,158,372 Modun Resources ASX:MOU $0.005 25% 55,000 Ark Mines ASX:AHK $0.05 22% 8,400 Resonance Health ASX:RHT $0.04 21.2% 609,971 Triple Energy ASX:TNP $0.006 20% 993,317 Vango Mining ASX:VAN $0.012 20% 83,766 Qrxpharma ASX:QRX $0.018 20% 601,909 Comops Limited ASX:COM $0.018 20% 300,000 Australian Proteins ASX:AYB $0.007 16.7% 281,500

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Wed, 22 Apr 2015 14:00:00 +1000 http://www.proactiveinvestors.com.au/companies/news/160158/these-are-the-biggest-asx-gainers-at-mid-day-61910.html
<![CDATA[News - Novogen, Coretrack among Tuesday’s volume leaders ]]> http://www.proactiveinvestors.com.au/companies/news/160157/novogen-coretrack-among-tuesdays-volume-leaders-61891.html Tuesday’s leading volume stocks on the ASX.

NameCodeLastChangeVolume Novogen Limited ASX:NRT $0.29 -30.1% 63,437,330 Coretrack Limited ASX:CKK $0.01 -9.1% 38,296,086 Axxis Technology Group ASX:AYG $0.001 -50% 29,860,746 Genetic Technologies ASX:GTG $0.042 -6.7% 25,631,735 Telstra Corporation ASX:TLS $6.19 0.3% 21,906,632 Fortescue Metals Group ASX:FMG $1.87 -1.1% 21,473,324 International Goldfields ASX:IGS $0.001 0% 17,500,000 SmartTrans Holdings ASX:SMA $0.023 9.5% 15,522,618 Environmental Clean Technologies ASX:ESI $0.011 10% 14,721,111 Stonehenge Metals ASX:SHE $0.029 -6.5% 14,649,339

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Wed, 22 Apr 2015 08:00:00 +1000 http://www.proactiveinvestors.com.au/companies/news/160157/novogen-coretrack-among-tuesdays-volume-leaders-61891.html
<![CDATA[News - Novogen, Focus Minerals are Wednesday’s most traded ]]> http://www.proactiveinvestors.com.au/companies/news/160156/novogen-focus-minerals-are-wednesdays-most-traded-61065.html Wednesday’s leading volume stocks on the ASX.

NameCodeLastChangeVolume Novogen Limited ASX:NRT $0.18 38.5% 50,672,489 Focus Minerals ASX:FML $0.009 0% 26,172,530 Redbank Copper ASX:RCP $0.001 0% 24,000,030 Mirabela Nickel ASX:MBN $0.065 20.4% 22,179,793 Alumina Limited ASX:AWC $1.78 -2.7% 20,260,846 Medibank Private ASX:MPL $2.51 1.6% 18,802,540 Aurizon Holdings ASX:AZJ $4.77 1.3% 18,723,717 Telstra Corporation ASX:TLS $6.32 -0.9% 18,648,048 Neuren Pharmaceuticals ASX:NEU $0.11 10% 17,890,390 Citigold Corporation ASX:CTO $0.02 5.3% 16,481,300

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Thu, 05 Mar 2015 08:00:00 +1100 http://www.proactiveinvestors.com.au/companies/news/160156/novogen-focus-minerals-are-wednesdays-most-traded-61065.html
<![CDATA[News - Novogen Limited identifies compounds to promote growth of brain stem cells ]]> http://www.proactiveinvestors.com.au/companies/news/160155/novogen-limited-identifies-compounds-to-promote-growth-of-brain-stem-cells-60133.html Novogen Limited (ASX:NRT; NASDAQ:NVGN) has identified a family of compounds with an ability to promote the growth and activity of normal brain stem cells.

This is in line with its approach of seeking drugs that would promote the migration of stem cells to the site of injury rather than through the introduction of externally cultured tissue stem cells.

This is a key proof-of-concept step forward in its regenerative medicine program to develop drugs capable of stimulating the function of brain tissue stem cells.

In April 2014, Novogen established a partnership with Genea Biocells, an Australian company with world-leading expertise in the production, growth and development of human embryonic stem cells.

The original purpose of that collaboration was to mine the company’s super-benzopyran drug technology platform for new therapies with the capacity to repair aberrant stem cells in people with various neurodegenerative disorders (eg. motor neurone disease) and musculodegenerative disorders (eg. Muscular dystrophies).

That program recently was extended to look at the ability of that same drug platform to stimulate the growth of healthy brain stem cells to create new nerve cells.

While the company is focused on developing anti-cancer drugs, this discovery demonstrates the potential of its intellectual property across many areas of medicine.



Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Fri, 16 Jan 2015 11:00:00 +1100 http://www.proactiveinvestors.com.au/companies/news/160155/novogen-limited-identifies-compounds-to-promote-growth-of-brain-stem-cells-60133.html
<![CDATA[News - Novogen Limited, Select Exploration among ASX % Gainers intra-day ]]> http://www.proactiveinvestors.com.au/companies/news/160154/novogen-limited-select-exploration-among-asx-gainers-intra-day-59658.html Wednesday’s ASX % Gainers intra-day.

NameCodeLastChangeVolume Coalbank Limited ASX:CBQ $0.004 100% 246,262 Blina Minerals ASX:BDI $0.002 100% 250,000 Kinetiko Energy ASX:KKO $0.04 60% 280,612 Novogen Limited ASX:NRT $0.25 51.5% 21,666,372 Rectifier Technologies ASX:RFT $0.003 50% 500,000 Select Exploration ASX:SLT $0.006 50% 31,599,507 Cervantes Corporation ASX:CVS $0.006 50% 450,000 Laneway Resources ASX:LNY $0.003 50% 946,593 Lakes Oil ASX:LKO $0.004 33.3% 5,250,000 MDS Financial Group ASX:MWS $0.004 33.3% 250,000

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Wed, 17 Dec 2014 14:00:00 +1100 http://www.proactiveinvestors.com.au/companies/news/160154/novogen-limited-select-exploration-among-asx-gainers-intra-day-59658.html
<![CDATA[News - Novogen raises funds to progress cancer drugs to the clinic ]]> http://www.proactiveinvestors.com.au/companies/news/160153/novogen-raises-funds-to-progress-cancer-drugs-to-the-clinic-58889.html Novogen (ASX:NRT) has raised $1,795,000 through its ASX bookbuild capital raising priced at $0.11 per share to progress its programs and consider a range of other funding offers.

The company also expects to soon receive a $1.45 million research and development tax rebate.

In August, the company received shareholder approval to issue 80 million shares and 80 million options.

The ASX bookbuild was conducted on this basis, resulting in the issue of 16,318,184 shares.

Each share comes with an attached 1 year unlisted options with an exercise price of $0.125.

Novogen has developed four new chemotherapy drugs and is now focused on bringing them into the clinic.



Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Wed, 12 Nov 2014 15:00:00 +1100 http://www.proactiveinvestors.com.au/companies/news/160153/novogen-raises-funds-to-progress-cancer-drugs-to-the-clinic-58889.html
<![CDATA[News - Novogen advances fight against ovarian cancer ]]> http://www.proactiveinvestors.com.au/companies/news/160152/novogen-advances-fight-against-ovarian-cancer-55678.html Novogen Limited (ASX:NRT; NASDAQ:NVGN) and CanTx Inc., its joint venture with Yale University, have revealed proof-of-concept success in pre-clinical studies confirming the potency of experimental drug, Trx-1, in the treatment of primary ovarian cancer when delivered into the peritoneal cavity.

Based on the potency seen in animal models to date, and the potential to prevent recurrence, Novogen and CanTx believe that Intra-Peritoneal Trx-1 could be utilized as a first-line therapy for ovarian cancer.

Trx-1 is being developed for the treatment of ovarian cancer, particularly for its ability to kill chemo-resistant ovarian cancer stem cells.

Novogen and CanTx plan to file an Investigational New Drug application in early 2015 and to start a Phase 1 study by mid-2015.

The data presented yesterday shows that Trx-1 can significantly retard the growth of highly chemo-resistant, human ovarian cancer stem cells in an animal model considered to be highly representative of the human situation.

Ovarian cancer is the most lethal of all gynecologic malignancies.

These tumors are made up of two distinct kinds of cells: cancer stem cells that initiate and perpetuate the tumor and which resist all forms of chemotherapy, and their daughter cells that, in most patients, respond initially to chemotherapy.

Where there is an initial response to therapy, it is because the chemo-sensitive daughter cells that make up the bulk of the tumor have responded.

But the parent cancer stem cells then respond by generating a new generation of daughter cells that now display the same level of chemo-resistance as the parent cells.

This is why when ovarian cancer recurs it is so difficult to treat.

Cantx's animal model is representative of the human situation where ovarian cancer generally is confined to the abdomen and the cells are free to spread, leading to multiple tumors often involving dozens or even hundreds of individual tumors.

These results elevate hopes for Trx-1 beyond the usual recovery of patients with late-stage ovarian cancer, to the prospect of incorporating it into first-line therapy in combination with conventional chemotherapy.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Wed, 18 Jun 2014 10:40:00 +1000 http://www.proactiveinvestors.com.au/companies/news/160152/novogen-advances-fight-against-ovarian-cancer-55678.html
<![CDATA[News - Novogen collaborates with Genea Biocells for degenerative diseases treatments ]]> http://www.proactiveinvestors.com.au/companies/news/160151/novogen-collaborates-with-genea-biocells-for-degenerative-diseases-treatments-54684.html Novogen Limited (ASX:NRT, NASDAQ:NVGN) is looking to trade higher after announcing a collaboration with Genea Biocells to accelerate testing of their super-benzopyran drugs for degenerative diseases of the nervous system and muscles.

Genea Biocells is a leader in the field of embryonic stem cells with genetic disorders.

Preliminary research conducted by both companies found that super-benzopyrans appear to be effective at promoting the ‘normalisation’ of stem cells associated with some forms of neurodegeneration and muscular dystrophy.

Super-benzopyran drugs have already been shown to be effective at killing cancer stem cells, which were previously considered resistant to anti-cancer therapy.

However in some of Novogen's studies, some of these drugs actually appeared to normalise both the behaviour and appearance of the cancer cells.

It was that observation that set Novogen on the path to testing their ability to achieve the same with stem cells carrying genetic disorders.

The cells have been sourced from embryos donated by couples undergoing in vitro fertilisation and pre-implantation genetic diagnosis; Genea is using those stem cell lines to identify potential clinical development candidates.

Novogen will partner with Genea Biocells to test the molecules in laboratory models across a range of degenerative diseases including infantile neuraxonal dystrophy, fascioscapularhumeral dystrophy, motor neurone disease, Sanfillipo syndrome and Alzheimer’s Disease.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Fri, 02 May 2014 18:20:00 +1000 http://www.proactiveinvestors.com.au/companies/news/160151/novogen-collaborates-with-genea-biocells-for-degenerative-diseases-treatments-54684.html
<![CDATA[News - Novogen establishes global collaboration for brain cancer drug development ]]> http://www.proactiveinvestors.com.au/companies/news/160150/novogen-establishes-global-collaboration-for-brain-cancer-drug-development-51328.html Novogen (ASX:NRT) has signed a Sponsored Research Agreement with Cornell University for research into drugs to treat brain tumours.

The Weill Cornell Medical College in New York will become the cornerstone of a collaboration across Europe, US, Asia and Australia involving universities and biotechnology companies seeking a treatment for the main form of primary brain cancer, glioblastoma multiforme.

The research program is focused on the super-benzopyran drug, Trilexium.

The brain cancer program parallels that of the Company’s efforts in the area of ovarian cancer through its joint venture, CanTx Inc, with Yale University.

CanTx has identified a Trilexium derivative as being effective against both ovarian cancer stem cells and ovarian cancer somatic cells.

The brain cancer program aims to identify a panel of drugs capable of providing a personalized approach to brain tumour chemotherapy.

The program is based on the high potency of Trilexium against glioblastoma multiforme cells, with both glioblastoma multiforme stem cells and somatic cells being killed at equivalent dosages.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Fri, 20 Dec 2013 09:40:00 +1100 http://www.proactiveinvestors.com.au/companies/news/160150/novogen-establishes-global-collaboration-for-brain-cancer-drug-development-51328.html
<![CDATA[News - Novogen files patents for novel anti-cancer drug technology ]]> http://www.proactiveinvestors.com.au/companies/news/160149/novogen-files-patents-for-novel-anti-cancer-drug-technology-50546.html Novogen Limited (ASX:NRT; Nasdaq:NVGN) has filed a family of provisional patents in the U.S. covering anti-tropomyosin (ATM) drug technology.

ATM drugs represent a novel approach to anti-cancer therapy, blocking the ability of cancer cells to divide.

Based on their action, ATMs belong to a class of anti-cancer drug known as anti-mitotics which remain among the most widely prescribed anti-cancer drugs after 40 years of use.

The current generation of anti-mitotic drugs, despite their widespread use, can have serious side-effects and many
types of cancer are inherently insensitive to them.

ATM drugs to date are showing an apparent lack of serious toxicity as well as an ability to kill cancer cells that are resistant to current anti-micotics.

Novogen is focusing its ATM drug development program on prostate cancer, melanoma and children’s cancers.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Tue, 26 Nov 2013 14:00:00 +1100 http://www.proactiveinvestors.com.au/companies/news/160149/novogen-files-patents-for-novel-anti-cancer-drug-technology-50546.html
<![CDATA[News - Novogen's drug destroys ovarian cancer stem cell tumours ]]> http://www.proactiveinvestors.com.au/companies/news/160148/novogens-drug-destroys-ovarian-cancer-stem-cell-tumours-50507.html Novogen Limited (ASX:NRT; Nasdaq:NVGN) should open and trade higher after demonstrating that lead drug Trilexium is effective in the destruction of ovarian cancer architecture.

Novogen's US subsidiary CanTx, in conjunction with Yale University, has shown that cancer stem cells isolated from the tumors of ovarian cancer patients are able to form self-renewing spheroids.

When injected into a mouse model, these spheroids form highly vascularized tumors mirroring that of the human disease.

Spheroids are mini-tumors and the ability of Trilexium to penetrate and to kill these tumor cell structures is a significant step forward for Trilexium.

Novogen proposes to deliver Trilexium into the peritoneal cavity where ovarian cancer originates and spreads.

By packing the drug into a targeted delivery system, delivery of significant quantities of the drug directly to
the usual multiple tumors is possible.

The American Cancer Society estimates that over 22,000 women will be diagnosed with ovarian cancer during 2013 and 14,230 American women will die from the disease.

It ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system.

Cancer stem cells are thought to be the tumor-initiating cells in many cancers responsible for both the production of the tumor mass and metastasis, and are highly resistant to chemotherapy and radiotherapy.

 

Proactive Investors is a market leader in the investment news space, providing ASX “Small and Mid-cap” company news, research reports, StockTube videos and One2One Investor Forums.

]]>
Mon, 25 Nov 2013 13:20:00 +1100 http://www.proactiveinvestors.com.au/companies/news/160148/novogens-drug-destroys-ovarian-cancer-stem-cell-tumours-50507.html
<![CDATA[News - Novogen forms JV with Yale University to treat ovarian cancer using its super-benzopyran drugs ]]> http://www.proactiveinvestors.com.au/companies/news/160147/novogen-forms-jv-with-yale-university-to-treat-ovarian-cancer-using-its-super-benzopyran-drugs-49929.html Novogen (ASX: NRT) has formed a joint venture with top research institution Yale University to develop personalised approaches to chemotherapy to fight ovarian cancer using its super-benzopyran drug technology.

Novogen will bring its drug technology platform to the CanTx joint venture (Novegen 85%) while Yale will bring its expertise with in vitro and in vivo test systems capable of evaluating the clinical potential of those drugs.

CanTx joint will be based near Yale’s campus in New Haven, Connecticut, and is expected to introduce its first product in 2014.

This will administered intra-peritoneally to women with ovarian cancer and is designed to seek out cancer cells and deliver a payload of a Novogen drug that has been shown to be highly cytotoxic against ovarian cancer cells including ovarian cancer stem cells.

While current chemotherapy is reasonably effective at killing the predominant somatic cancer cells, it does not kill the cancer stem cells leading to about 70% of patients experiencing tumour recurrence.

In contrast, Novogen’s super-benzopyran family of drugs shows a high degree of activity against ovarian cancer stem cells

Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Thu, 07 Nov 2013 10:00:00 +1100 http://www.proactiveinvestors.com.au/companies/news/160147/novogen-forms-jv-with-yale-university-to-treat-ovarian-cancer-using-its-super-benzopyran-drugs-49929.html
<![CDATA[News - Novogen's shares continue to firm ]]> http://www.proactiveinvestors.com.au/companies/news/160146/novogens-shares-continue-to-firm-49578.html Novogen (ASX: NRT, NASDAQ: NVGN) shares gained 25.6% yesterday to close at $0.245 on strong volume of close to 8.5 million shares.

At the start of the month the company was trading at around $0.17.

Novogen is focused on the development of drug strategies that will deliver  personalized chemotherapy based.

This is based on the effective elimination of cancer stem cells and somatic cancer cells across a range of genotypes.

Earlier in the month the company acquired a novel drug technology that will be developed as a potentially major class of cancer drugs known as anti-tropomyosins (anti-Tms).

Anti-Tm drugs will join the Company’s growing pipeline of super-benzopyran drugs, including Trilexium and related analogs.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Tue, 29 Oct 2013 09:20:00 +1100 http://www.proactiveinvestors.com.au/companies/news/160146/novogens-shares-continue-to-firm-49578.html
<![CDATA[News - Novogen Limited launches funding initiative ]]> http://www.proactiveinvestors.com.au/companies/news/160145/novogen-limited-launches-funding-initiative-45144.html Biotechnology company Novogen Limited (ASX: NRT) has been granted a trading halt this morning by the ASX, with its shares placed in pre-open, pending an announcement of a proposed material capital raising.

Novogen is focused on the development of a family of novel anti-cancer drugs based on comprehensive anti-cancer activity against both cancer cells and cancer stem cells. The company’s inaugural drug candidate is CS-6.

CS-6 belongs to a new class of drug candidates intended to treat most forms of cancer in a comprehensive manner, targeting both cancer cells and their progenitor cells, cancer stem cells.

The halt will last until the earlier of an announcement being made to the market, or the opening of trade on Friday 5th July 2013.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.   

]]>
Wed, 03 Jul 2013 13:00:00 +1000 http://www.proactiveinvestors.com.au/companies/news/160145/novogen-limited-launches-funding-initiative-45144.html
<![CDATA[News - Novogen's Graham Kelly to showcase anti-cancer compound at 'Stars in 2013' ]]> http://www.proactiveinvestors.com.au/companies/news/160144/novogens-graham-kelly-to-showcase-anti-cancer-compound-at-stars-in-2013-43866.html Novogen (ASX: NRT) has set itself the lofty goal of conquering cancer by developing the CS-6 comprehensive cancer therapy and has already completed screening of its second generation of super-benzopyrans in its ongoing drug discovery platform.

Chief executive officer Dr Graham Kelly will present to investors at the Proactive Investors’ "Stars in 2013 Series" Investor Forum on Tuesday, 4th June 2013.

REGISTER HERE or call (02) 9299 5001 for more information.

With CS-6, the company’s proprietary ‘bend’ technology constructs new compounds of differing shape and increasing complexity to discover new lead candidates with potent activity against various types of cancer stem cells and regular cancer cells.

Laboratory screening now has identified melanoma and pancreatic cancer as being highly sensitive to second-generation compounds, with two compounds showing particularly high potency.

These are all steps in Novogen’s ultimate goal of providing personalised comprehensive chemotherapy to cancer patients (commencing with ovarian cancer) based on the ability of a family of super-benzopyran drugs to target a range of phenotype/genotype cancer cells.

FORUM DETAILS:

Start time:  5:30pm - Please arrive by 5:15pm.

Date: Tuesday 4th June 2013

Place: Radisson Blu Hotel - Cnr Pitt & O'Connell Street

Five Industrial companies presenting, with Lucky Door Prizes and a wine and canapé reception where you can personally interact with the presenting MD's & CEOs.

The event is FREE to attend but make sure you REGISTER today as the seats are filling quickly already.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Thu, 30 May 2013 10:08:00 +1000 http://www.proactiveinvestors.com.au/companies/news/160144/novogens-graham-kelly-to-showcase-anti-cancer-compound-at-stars-in-2013-43866.html
<![CDATA[News - Novogen Oncology makes further progress in drug discovery platform ]]> http://www.proactiveinvestors.com.au/companies/news/160143/novogen-oncology-makes-further-progress-in-drug-discovery-platform-42951.html Australian and NASDAQ listed Novogen (ASX:NRT, NASDAQ: NVGN) has completed screening of its second generation of super-benzopyrans in its ongoing drug discovery platform.

Novogen's approach is to develop a family of novel anti-cancer drugs based on comprehensive anti-cancer activity against both cancer cells and cancer stem cells.

The company’s current lead drug candidate, CS-6, is a product of the first generation of compounds.

The discovery program aims to use Novogen's proprietary ‘bend’ technology to both strengthen its intellectual property position as well as identifying new lead compounds.


Melanoma and pancreatic cancer

Using CS-6 as the starting point, the program constructs new compounds of differing shape and increasing complexity. The objective is to discover new lead candidates with potent activity against various types of cancer stem cells and regular cancer cells.

Laboratory screening now has identified melanoma and pancreatic cancer as being highly sensitive to second-generation compounds, with two compounds showing particularly high potency.

Newly appointed Novogen chief scientific officer, Dr David Brown, said today, “the identification of two new hit compounds against pancreatic cancer and melanoma nicely complements our pipeline of CS-6 with its key indications of glioblastoma and ovarian cancer.

“Our task now is to decide which of these two new compounds we will fast-track through to the clinic in parallel with CS-6.”

Today's results highlight the company's belief in the potential ability to ‘bend’ small molecules to deliver specific activity against specific forms of cancer, and "to meet our mission of developing a family of drugs providing comprehensive activity against both regular cancer cells and their progenitor cells.”


About CS-6

CS-6 belongs to a new class of drug candidates intended to treat most forms of cancer in a comprehensive manner, targeting both cancer cells and their progenitor cells, cancer stem cells.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Tue, 07 May 2013 13:50:00 +1000 http://www.proactiveinvestors.com.au/companies/news/160143/novogen-oncology-makes-further-progress-in-drug-discovery-platform-42951.html
<![CDATA[News - Novogen raising up to $5.8M to meet cancer drug candidate CS-6 obligations ]]> http://www.proactiveinvestors.com.au/companies/news/160142/novogen-raising-up-to-58m-to-meet-cancer-drug-candidate-cs-6-obligations-42154.html Novogen (ASX: NRT) is raising up to $5.8 million to commit to contractual obligations for its lead anti-cancer drug candidate CS-6.

The funds will be raised through a Share Purchase Plan offering existing shareholders up to $15,000 worth of new shares priced at $0.17 each.

This represents a 20% discount on the average market price over the last five days on which sales in the company’s shares were recorded before the plan was announced today.

Proceeds will also be used to conduct studies to identify other potential clinical options for CS-6, creating a pipeline of other potential drug candidates as well as provide working capital.

Novogen had late last month received acceptances to raise A$2.5 million by way of a share placement.

The company will issue shares at $0.166 each, a 20% discount to the closing price of $0.20 on 10 April 2013.

It added that once the proceeds of the placement and SPP are received, it will assess whether or not additional funds are needed at this stage.

Should the directors decide that more funds are required, it is currently anticipated that Novogen would not need more than $10 million, including the funds raised by the placement and SPP.

Earlier this month Novogen announced that it had made a breakthrough with the successful isolation of the most potent form of CS-6, the company’s lead anti-cancer drug candidate.

Novogen's goal is to develop the first comprehensive cancer therapy capable of killing both standard tumour cells and cancer stem cells.

The company’s strategy is to raise money over the coming three years on a progressive basis rather than in one upfront raising to minimise shareholder dilution.

Novogen had about $1 million in cash as of 31 December 2012.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Wed, 17 Apr 2013 16:30:00 +1000 http://www.proactiveinvestors.com.au/companies/news/160142/novogen-raising-up-to-58m-to-meet-cancer-drug-candidate-cs-6-obligations-42154.html
<![CDATA[News - Novogen to grow cash reserves by A$2.5M ]]> http://www.proactiveinvestors.com.au/companies/news/160141/novogen-to-grow-cash-reserves-by-a25m-41977.html Novogen (ASX: NRT) has received acceptances to raise A$2.5 million by way of a share placement.

The company will issue shares at $0.166 each, a 20% discount to the closing price of $0.20 on 10 April 2013.

Novogen plans to use the funds to take its cancer drug, CS-6, through a pre-clinical program in preparation for both brain and ovarian cancer indications.

Earlier this week Novogen announced that it had made a breakthrough with the successful isolation of the most potent form of CS-6, the company’s lead anti-cancer drug candidate.

Novogen's goal is to develop the first comprehensive cancer therapy capable of killing both standard tumour cells and cancer stem cells.

The company’s strategy is to raise money over the coming three years on a progressive basis rather than in one upfront raising to minimise shareholder dilution.

Novogen is also considering undertaking a share purchase plan.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Fri, 12 Apr 2013 15:10:00 +1000 http://www.proactiveinvestors.com.au/companies/news/160141/novogen-to-grow-cash-reserves-by-a25m-41977.html
<![CDATA[News - Novogen Limited to increase funding levels for cancer research ]]> http://www.proactiveinvestors.com.au/companies/news/160140/novogen-limited-to-increase-funding-levels-for-cancer-research-41900.html Cancer drug development company Novogen Limited (ASX: NRT) is preparing a capital raising announcement, with the ASX granted the company a trading halt this morning - with its shares placed in pre-open.

Earlier in the week Novogen announced that it had made a breakthrough with the successful isolation of most potent form of CS-6, which is the lead anti-cancer drug candidate being developed by the company as a first-in-class comprehensive cancer therapy. Novogen aims to bring CS-6 to market as a treatment for late-stage brain cancer and late-stage ovarian cancer.

Novogen's goal is to develop the first comprehensive cancer therapy capable of killing both standard tumour cells and cancer stem cells.

The halt will last until the earlier of an announcement being made to the market, or the opening of trade on Monday 15th April 2013.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Thu, 11 Apr 2013 11:20:00 +1000 http://www.proactiveinvestors.com.au/companies/news/160140/novogen-limited-to-increase-funding-levels-for-cancer-research-41900.html
<![CDATA[News - Novogen isolates most potent form of anti cancer drug candidate CS-6 ]]> http://www.proactiveinvestors.com.au/companies/news/160139/novogen-isolates-most-potent-form-of-anti-cancer-drug-candidate-cs-6-41721.html Novogen (ASX:NRT) has successfully isolated the most potent form of CS-6, its lead anti cancer drug candidate, allowing the manufacturing of both left and right hand forms of enantiomers.

The significance of this is that enantiomers often differ in their biological activity, with one form being more active than the other form. This difference can lead to the weakest form inhibiting the most active form.

Where that happens, the enantiomers need to be separated and used in isolation.

As CS-6 has already shown promise in pre-clinical studies, Novogen has recently undertaken the manufacturing of pure left and right hand forms.

The two CS-6 enantiomers were screened in vitro for activity against brain cancer cell lines. Analysis of this data shows that on CS-6 enantiomer is approximately 200 times more active than the alternate form of CS-6 against all brain cancer cell lines tested.

The indication that one form of CS-6 is active at nanomloar concentrations against a broad spectrum of brain cancer lines indicates that the earlier potencies seen against cancer cells and stem cells are likely to be even greater.

CS-6 belongs to a new family of drugs known as super-benzopyrans which Novogen has developed and which have a number of design features purposely built into them such as the ability to kill both cancer stem cells and their daughter cells; the ability to cross the blood-brain barrier, and improved bioavailability.

It had a cash balance of $1 million at the end of December 2012.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Mon, 08 Apr 2013 15:10:00 +1000 http://www.proactiveinvestors.com.au/companies/news/160139/novogen-isolates-most-potent-form-of-anti-cancer-drug-candidate-cs-6-41721.html
<![CDATA[News - Novogen confirms potency of CS-6 drug against cancer stem cells ]]> http://www.proactiveinvestors.com.au/companies/news/160138/novogen-confirms-potency-of-cs-6-drug-against-cancer-stem-cells-41495.html Novogen (ASX:NRT) has confirmed the potency of its CS-6 drug against cancer stem cells in follow up studies.

It had earlier reported data from a sighting study that showed that the experimental anti cancer drug was highly cytotoxic in the laboratory against ovarian cancer stem cells.

The follow up study examined the effect of the drug against a range of other OCSC cell lines, including cell lines virtually indestructible by both standard-of-care and experimental anti-cancer drugs.

It also looked at the effect of CS-6 on the differentiated daughter cells of these cancer stem cells, mirroring the situation in patients with ovarian cancer where the cancer responds to chemotherapy initially, but then recurs.

Recurrence in that case being the result of the chemo-resistant cancer stem cells in the tumor surviving the chemotherapy to produce a new population of daughter cells with increased resistance to chemotherapy.

But the CS-6 proved to be highly cytotoxic against all cancer stem cell lines tested with the cytotoxicity evident as early as 4 hours.

The results could potentially pave the way for developing first-in-class drugs offering comprehensive anti-cancer therapy.

CS-6 belongs to a new family of drugs known as super-benzopyrans which Novogen has developed and which have a number of design features purposely built into them such as the ability to kill both cancer stem cells and their daughter cells; the ability to cross the blood-brain barrier, and improved bioavailability.

It had a cash balance of $1 million at the end of December 2012.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Wed, 03 Apr 2013 10:10:00 +1100 http://www.proactiveinvestors.com.au/companies/news/160138/novogen-confirms-potency-of-cs-6-drug-against-cancer-stem-cells-41495.html
<![CDATA[News - Novogen shares soar on the potential of its experimental anti ovarian cancer drug ]]> http://www.proactiveinvestors.com.au/companies/news/160137/novogen-shares-soar-on-the-potential-of-its-experimental-anti-ovarian-cancer-drug-39686.html Novogen's (ASX:NRT) share price more than doubled after a study showed that its experimental anti-ovarian cancer drug CS-6 was highly active against ovarian cancer stem cells.

Share were up almost 311%, reaching a high of $0.37 a share.

While the drug has shown potent anti cancer activity against cancer cells, the study was designed to find whether the drug would also be effective against cancer stem cells.

Cancer stem cells have been identified in a range of cancers including ovarian, brain cancers and leukaemia and are almost completely resistant to radiotherapy and standard anti-cancer drugs.

With CS-6 showing dual activity, it would mark the drug as having significant potential as a comprehensive chemotherapy, targeting both the minority cancer stem cell as well as the majority non stem cells.

The study was done by Mazor Oncology, a spin off company of Yale Universtiy that has expertise in cancer stem cells.

Studies performed in the laboratory of Dr. Gil Mor at Yale University have identified and characterized ovarian cancer stem cells as the source of ovarian cancer recurrence.

Targeting these cells, therefore, represent a critical approach to prevent recurrence, the main cause of mortality in patients with ovarian cancer.

In laboratory tests conducted since Novogen acquired its new Triaxial drug technology, CS-6 has proved highly effective at stopping the growth of these cancer stem cells, eventually causing them to die.

The initial studies at Mazor Oncology show a highly effective cytotoxic effect on ovarian cancer stem cells, at low concentrations and within a short period of time.

The CS-6 belongs to a new class of drug candidates known as super benzopyrans displaying potent anti cancer activity.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Mon, 18 Feb 2013 14:20:00 +1100 http://www.proactiveinvestors.com.au/companies/news/160137/novogen-shares-soar-on-the-potential-of-its-experimental-anti-ovarian-cancer-drug-39686.html
<![CDATA[News - Novogen to acquire Australian bio-pharmaceutical company ]]> http://www.proactiveinvestors.com.au/companies/news/160136/novogen-to-acquire-australian-bio-pharmaceutical-company-35739.html Novogen (ASX: NRT) has plans to acquire all of the shares in privately owned, Australian bio-pharmaceutical company Triaxial Pharmaceuticals for A$1.88 million.

The two companies have signed a term sheet covering the deal that will be satisfied via a combination of Novogen shares and debt.

The proposed transaction is conditional on completion of Novogen’s previously announced capital reduction and remains subject to the execution of legal documentation.

Triaxial, which was established in 2009, was formed to develop a technology platform addressing the problem of certain families of small molecular drugs where there is an inherent inflexibility in their chemical structure.

The company is initially using its technology to create a family of molecules known as super benzopyrans which target a range of key signal transduction pathways that are at the heart of multi-drug resistance in cancer cells.


Proactive Investors is a market leader in the investment news space, providing ASX “Small and Mid-cap” company news, research reports, StockTube videos and One2One Investor Forums.

]]>
Mon, 12 Nov 2012 16:00:00 +1100 http://www.proactiveinvestors.com.au/companies/news/160136/novogen-to-acquire-australian-bio-pharmaceutical-company-35739.html
<![CDATA[News - Novogen reports high response to cancer treatment ]]> http://www.proactiveinvestors.com.au/companies/news/160135/novogen-reports-high-response-to-cancer-treatment--35539.html Novogen's (ASX: NRT) MEI Pharma (NASDAQ: MEIP) has reported high response rates in a clinical trial of its cancer treatment, Pracinostat, in combination with azacitidine in patients with myelodysplastic syndrome (MDS).

This follows yesterday’s announcement the company will bank US$27.5 million after receiving commitments for a private placement.

Importantly, with this new data in hand, combined with the capital raising, MEI Pharma expects to be in a position to rapidly advance to the next stage of development.

The company plans to initiate a randomised phase two trial of Pracinostat in combination with azacitidine in patients with MDS by the June quarter of next year.

MDS is the name of a group of conditions that occur when the blood-forming cells in the bone marrow are damaged. It can lead to acute myeloid leukemia, a cancer that starts inside bone marrow.

The recent data is particularly compelling given that most patients in the study had treatment-related MDS and expressed high risk cytogenetic abnormalities, both of which carry a poor prognosis.

Pracinostat is a selective inhibitor of a group of enzymes called histone deacetylases (HDAC).

There are currently two HDAC inhibitors approved by the U.S. Food and Drug Administration (FDA) for the treatment of cutaneous T-cell lymphoma, one of which is also approved for the treatment of peripheral T-cell lymphoma.

Pracinostat has shown evidence of single-agent activity in multiple clinical trials, including advanced hematologic malignancies such as MDS, acute myeloid leukemia and myelofibrosis.

The inhibitor has also demonstrated pre-clinical activity in hematologic disorders and solid tumours when used alone or in combination with a wide range of therapies in laboratory studies.

Pracinostat has been generally well tolerated in clinical testing of more than 150 patients, with readily manageable side effects often associated with drugs of this class.


Proactive Investors is a market leader in the investment news space, providing ASX “Small and Mid-cap” company news, research reports, StockTube videos and One2One Investor Forums.

]]>
Wed, 07 Nov 2012 11:10:00 +1100 http://www.proactiveinvestors.com.au/companies/news/160135/novogen-reports-high-response-to-cancer-treatment--35539.html
<![CDATA[News - Novogen secures US$27.5M placement ]]> http://www.proactiveinvestors.com.au/companies/news/160134/novogen-secures-us275m-placement-35477.html Novogen's (ASX: NRT) MEI Pharma (NASDAQ: MEIP) will bank US$27.5 million after receiving commitments for a private placement.

The funds will be used to advance the clinical development of Pracinostat, an oral histone deacetylase (HDAC) inhibitor for the treatment of cancer, and its isoflavone-based drug candidates.

Australia-based Novogen conducts research and development on oncology therapeutics through U.S.-based MEI Pharma.

Under the private placement, MEI Pharma will issue 55 million shares of its common stock and warrants to purchase up to 38.5 million additional shares of common stock.

Each unit, consisting of one share of common stock and a warrant to purchase 0.7 of a share of common stock, will be issued at US$0.50. The warrants will be exercisable at US$0.52 per share and expire five years from the date of issue.

The financing was led by new investors Vivo Ventures and New Leaf Venture Partners with participation from additional institutional investors, including RA Capital Management and Three Arch Opportunity Fund.


Pracinostat

Pracinostat has been tested in more than 150 patients in multiple phase one and exploratory phase two clinical trials, including advanced hematologic malignancies such asmyelodysplastic syndrome, acute myeloid leukemia and myelofibrosis.

MEI Pharma plans to initiate a randomised phase two trial of Pracinostat in combination with standard-of-care in at least one hematologic malignancy toward the middle of 2013.

The company is also developing two oncology drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344.

Results from a phase one trial of intravenous ME-143 in heavily treated patients with solid refractory tumours were presented at the American Society of Clinical Oncology Annual Meeting in June 2012.

A phase one clinical trial of intravenous ME-344 in patients with solid refractory tumours is ongoing.


Proactive Investors is a market leader in the investment news space, providing ASX “Small and Mid-cap” company news, research reports, StockTube videos and One2One Investor Forums.

]]>
Tue, 06 Nov 2012 11:10:00 +1100 http://www.proactiveinvestors.com.au/companies/news/160134/novogen-secures-us275m-placement-35477.html
<![CDATA[News - Novogen: Phase I clinical trials for anti-tumour drug begin in the U.S. ]]> http://www.proactiveinvestors.com.au/companies/news/160133/novogen-phase-i-clinical-trials-for-anti-tumour-drug-begin-in-the-us-29547.html Novogen (ASX: NRT, NASDAQ: NVGN) is continuing to progress its oncology drug candidate, ME-344, in the United States, with the first patients dosed in a Phase I clinical trial.

The Phase I clinical trial is designed to test the safety and tolerability of intravenous ME-344 in escalating dose cohorts, from 1.2 milligrams per kilogram up to 20 milligrams per kilogram.

It will also serve to characterise the pharmacokinetic profile of ME-344 and describe any preliminary clinical anti-tumour activity observed.

The trial is focused on patients with refractory solid tumours, and aims to enrol up to 24 patients in up to five cohorts.

Patients will be administered intravenous infusions of ME-344 weekly over three weeks, and will continue dosing after a safety assessment, if a clinical benefit is determined.

Final safety and pharmacokinetic data from the trial is expected in the first half of 2013. Results from the Phase I trial will help to optimise the design of Phase II efficacy studies.

Preclinical studies into ME-344 showed that the drug displayed compelling anti-tumour activity.

The Phase I clinical trial is being run by Novogen’s U.S. subsidiary Marshall Edwards (NASDAQ: MSHL), in collaboration with the Sarah Cannon Research Institute at three sites in Florida, Oklahoma and Nashville.



Proactive Investors is a market leader in the investment news space, providing ASX “Small and Mid-cap” company news, research reports, StockTube videos and One2One Investor Forums.

]]>
Thu, 31 May 2012 10:00:00 +1000 http://www.proactiveinvestors.com.au/companies/news/160133/novogen-phase-i-clinical-trials-for-anti-tumour-drug-begin-in-the-us-29547.html
<![CDATA[News - Novogen: Marshall Edwards advances towards clinical trials of cancer treatment in the U.S. ]]> http://www.proactiveinvestors.com.au/companies/news/160132/novogen-marshall-edwards-advances-towards-clinical-trials-of-cancer-treatment-in-the-us-26134.html Novogen’s (ASX: NRT) subsidiary Marshall Edwards has submitted an Investigational New Drug application to the U.S. Food and Drug Administration (FDA) to begin clinical testing for its oncology drug ME-344.

Marshall Edwards is planning a Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumours following approval by the FDA.

ME-344 is the company’s lead mitochondrial inhibitor designed to treat tumour cells by inducing a rapid loss of cellular energy, leading to the inhibition of the mammalian target of rapamycin, a protein that regulates cell growth.

Meanwhile, Marshall Edwards has begun dosing the fourth cohort in its Phase I clinical trial of intravenous ME-143 in patients with solid refractory tumours.

Highlighting the rapid progression of Marshall Edwards’ cancer and tumour treatments, the company went from submitting an Investigational New Drug application to the FDA to beginning clinical testing of ME-143 in less than seven months.

The company expects to collect final safety and pharmacokinetic data from the Phase I trial of ME-143 by June.

Marshall Edwards is nearing completion of enrolment of patients in the trial and is preparing for Phase II trials. 

]]>
Wed, 07 Mar 2012 12:40:00 +1100 http://www.proactiveinvestors.com.au/companies/news/160132/novogen-marshall-edwards-advances-towards-clinical-trials-of-cancer-treatment-in-the-us-26134.html
<![CDATA[News - Novogen receives US cancer treatment patent ]]> http://www.proactiveinvestors.com.au/companies/news/160131/novogen-receives-us-cancer-treatment-patent-23767.html Novogen (ASX: NRT, Nasdaq: NVGN) subsidiary Marshall Edwards (Nasdaq: MSHL) has been issued a new method of use patent for its cancer and tumour treatments.

The new patent from the US Patent and Trademark Office covers the use of a number of the company’s mitochochondrial inhibitor compounds, including lead drug candidate ME-344, in the treatment of cancer.

These compounds treat tumour cells by inducing a rapid loss of cellular energy, leading to the inhibition of the mammalian target of rapamycin, a protein that regulates cell growth.

Marshall Edwards has completed the necessary pre-clinical animal toxicity studies to support the submission of an Investigational New Drug application for ME-344 in the March quarter.

The company then plans to initiate a Phase I clinical trial of intravenous ME-344.

The patent is expected to provide protection until September 2025.

]]>
Wed, 04 Jan 2012 09:04:00 +1100 http://www.proactiveinvestors.com.au/companies/news/160131/novogen-receives-us-cancer-treatment-patent-23767.html
<![CDATA[News - Novogen shares soar 83% in morning trade after overnight Nasdaq jump ]]> http://www.proactiveinvestors.com.au/companies/news/160130/novogen-shares-soar-83-in-morning-trade-after-overnight-nasdaq-jump-15012.html Biotechnology company Novogen (ASX: NRT, Nasdaq: NVGN) has beaten the ASX to a price query saying the company is 'unaware of any specific reasons' for the sudden share price spike, even before the ASX had a chance to issue a price 'speeding ticket'.

The 83% jump in morning trade on the ASX is a function of the increased share activity overnight on the Nasdaq.

Volume was also high with 1.5 million shares changing hands in the first hour of trade.

Novogen has a consumer healthcare business, conducts research and development on oncology therapeutics through its 71.3% owned subsidiary, Marshall Edwards, Inc., and is developing glucan technology through its 80.7% owned subsidiary, Glycotex, Inc.

 

]]>
Tue, 29 Mar 2011 11:18:00 +1100 http://www.proactiveinvestors.com.au/companies/news/160130/novogen-shares-soar-83-in-morning-trade-after-overnight-nasdaq-jump-15012.html